Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
151
-
Total 13F shares, excl. options
-
49,472,050
-
Shares change
-
-1,072,002
-
Total reported value, excl. options
-
$1,246,067,821
-
Value change
-
-$26,647,818
-
Put/Call ratio
-
1.49%
-
Number of buys
-
82
-
Number of sells
-
-49
-
Price
-
$25.14
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2020
172 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2020.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 151 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49,472,050 shares
of 104,661,494 outstanding shares and own 47.27% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4,881,188 shares), JPMORGAN CHASE & CO (4,079,056 shares), WELLINGTON MANAGEMENT GROUP LLP (3,562,591 shares), Essex Woodlands Management, Inc. (3,342,047 shares), VANGUARD GROUP INC (3,152,376 shares), ArrowMark Colorado Holdings LLC (2,762,806 shares), ALLIANCEBERNSTEIN L.P. (2,603,516 shares), FRANKLIN RESOURCES INC (2,578,033 shares), JENNISON ASSOCIATES LLC (2,286,042 shares), and Capital World Investors (2,130,000 shares).
This table shows the top 151 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.